Reimbursement in Europe: a continent under pressure
This article was originally published in Clinica
Amanda Maxwell rounds up how European countries are changing their reimbursement procedures to cope with cost-containment pressures.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.